New data shows that government-funded health insurance plans in the United States provide the majority of coverage for ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

Novo Nordisk has launched its weight-loss drug Wegovy in China after it was approved by local health authorities in June. It ...

Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage ...

The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...

Stroke was the fourth leading cause of death in the U.S. in 2023, according to the Centers for Disease Control and Prevention, and more than half a million Americans have a stroke every year. But up ...

More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug ...

In interviews with Reuters, eight U.S. obesity specialists at universities and large health systems described a different ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity.